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ABSTRACT
Objectives: This article reports relationships between
serum cytokine levels and patient-reported levels of
fatigue, in the chronic immunological condition
primary Sjögren’s syndrome (pSS).
Methods: Blood levels of 24 cytokines were measured
in 159 patients with pSS from the United Kingdom
Primary Sjögren’s Syndrome Registry and 28 healthy
non-fatigued controls. Differences between cytokines in
cases and controls were evaluated using Wilcoxon test.
Patient-reported scores for fatigue were evaluated,
classified according to severity and compared with
cytokine levels using analysis of variance. Logistic
regression was used to determine the most important
predictors of fatigue levels.
Results: 14 cytokines were significantly higher in
patients with pSS (n=159) compared to non-fatigued
healthy controls (n=28). While serum levels were
elevated in patients with pSS compared to healthy
controls, unexpectedly, the levels of 4 proinflammatory
cytokines—interferon-γ-induced protein-10 (IP-10)
(p=0.019), tumour necrosis factor-α (p=0.046),
lymphotoxin-α (p=0.034) and interferon-γ (IFN-γ)
(p=0.022)—were inversely related to patient-reported
levels of fatigue. A regression model predicting fatigue
levels in pSS based on cytokine levels, disease-specific
and clinical parameters, as well as anxiety, pain and
depression, revealed IP-10, IFN-γ (both inversely), pain
and depression (both positively) as the most important
predictors of fatigue. This model correctly predicts
fatigue levels with reasonable (67%) accuracy.
Conclusions: Cytokines, pain and depression appear
to be the most powerful predictors of fatigue in pSS.
Our data challenge the notion that proinflammatory
cytokines directly mediate fatigue in chronic
immunological conditions. Instead, we hypothesise
that mechanisms regulating inflammatory responses
may be important.
INTRODUCTION
Fatigue is a signiﬁcant and debilitating
symptom affecting 25% of the general
Key messages
What is already known about this subject?
▸ ‘Sickness behaviour’ describes a range of symp-
toms, characterised by fatigue and mediated by
proinflammatory cytokines, which occur in mice
after injection of lipopolysaccharide, and pro-
vides an animal model of acute fatigue within
the context of infection or a proinflammatory
state.
▸ However, inflammation does not necessarily cor-
relate with fatigue in a number of autoimmune
conditions, suggesting that inflammation may
not be a direct mechanism behind persistent
fatigue within the context of chronic conditions.
What does this study add?
▸ The finding that certain proinflammatory cyto-
kines decrease as patient-reported fatigue
increases in primary Sjögren’s syndrome (pSS)
is a novel finding.
▸ This may improve understanding of biological
basis of fatigue and help to direct future fatigue
research towards investigating dysregulation of
inflammation rather than inflammation itself.
How might this impact on clinical practice?
▸ This may help to explain why levels of inflamma-
tion do not appear to correlate with patient-
reported fatigue levels within the pSS popula-
tion, and why treating inflammation does not
necessarily improve fatigue in patients with
chronic inflammatory conditions such as pSS.
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population resulting in considerable morbidity and eco-
nomic cost.1–3 It is a key feature of numerous chronic
diseases, being particularly prominent in many rheum-
atological conditions including primary Sjögren’s syn-
drome (pSS).4 5
Although the biological basis of fatigue is unclear, it
has been suggested that proinﬂammatory mechanisms
play a central role, since fatigue is seen in a number of
conditions with underlying immune dysregulation, and
is a well-documented postinfective symptom.6–8 This was
ﬁrst suggested by a constellation of symptoms, charac-
terised by fatigue and termed ‘sickness behaviour’, seen
in mice after injection of lipopolysaccharide.9 Sickness
behaviour is considered as an evolutionarily adaptive
behavioural response to infection facilitating speedy
recovery, minimising energy-expenditure and reducing
environmental risks when an organism is in a weakened
state during and following an infection. It is mediated by
proinﬂammatory cytokines, thus supporting inﬂamma-
tion as a central component in the pathophysiology of
fatigue.8 10 In particular, recent research has focused on
the role of proinﬂammatory cytokines in mediating
fatigue,11–14 particularly in the context of chronic
fatigue syndrome (CFS). However, levels of inﬂamma-
tion in some rheumatological diseases, such as rheuma-
toid arthritis (RA), systemic lupus erythematosus (SLE)
and pSS, do not necessarily correlate with fatigue scores,
suggesting that there may be a complex range of positive
and negative feedback loops contributing to fatigue in
autoimmune conditions.15 16
PSS is a useful disease model for research into the bio-
logical basis of fatigue. It has clear diagnostic criteria
providing a well-deﬁned patient group, in whom
immunosuppressive medications—potentially altering
immune and inﬂammatory processes—are less com-
monly used compared with patients with other auto-
immune diseases. There is also wide variability between
patients with pSS in terms of the fatigue they experi-
ence. In pSS, fatigue does not appear to correlate well
with systemic or glandular disease activity, suggesting
that there may be separate pathophysiological mechan-
isms for fatigue and disease activity.15
Other studies, in pSS as well as in rheumatological dis-
eases such as RA and SLE, have shown that measures of
fatigue are not associated with markers of inﬂammation
and disease activity scores.17–20 However, such studies
have not examined such a range of cytokines, making
our study unique. In addition to this, patients in such
studies with RA and SLE usually take a number of
disease-modifying or immune-suppressive medications,
which could affect their inﬂammatory proﬁles, unlike
patients with pSS who are less-frequently prescribed
potent immune-suppressive medications.
Using gene set enrichment analysis of gene expression
data from 133 patients with pSS discordant for fatigue,
we have recently identiﬁed several biological pathways
that are discordant between fatigued and non-fatigued
patients with pSS. Furthermore, using support vector
machine classiﬁcation, a 55-gene signature was identi-
ﬁed, which is predictive of fatigue level. Interestingly,
none of the biological pathways or the 55 genes were
overtly related to inﬂammation.21 Other studies have
found that pain and depression were more strongly asso-
ciated with fatigue in RA and SLE than disease activity
scores or inﬂammatory markers.18 19 22 These observa-
tions indicate that, at least in the setting of a chronic dis-
order, inﬂammatory molecules may not directly result in
fatigue.
This study examines patients from the United Kingdom
Primary Sjögren’s Syndrome Registry (UKPSSR).23 This
registry consists of a large cohort of clinically well-
characterised patients with pSS and matched controls. We
have used UKPSSR data here to attempt to determine
whether there is a relationship between serum cytokine
levels and patient-reported levels of fatigue. We hypothe-
sise that there will be a signiﬁcant difference in serum
cytokine levels between cases with pSS and controls, and
between the higher and lower fatigue scores within the
pSS patient group. We also aimed to determine import-
ant predictors of fatigue in pSS to initiate further investi-
gation of these factors.
METHODS
Experimental design
The objective of this study was to analyse cytokine
and fatigue levels in patients with pSS in order to deter-
mine whether there is a relationship between cytokines
and fatigue in pSS. We also used clinical and biological
data to ascertain the most important predictors of
fatigue within this patient group. Cytokine proﬁles were
compared to healthy non-fatigued controls to examine
differences between these populations. This was a case–
control study using results from analysis of serum
samples from a patient registry along with clinical data
collected contemporaneously at the time of recruitment
onto the patient registry.
Study population
Patients were selected from the UKPSSR (http://www.
sjogrensregistry.org), which holds detailed clinical,
laboratory and demographic data on over 700 patients
with pSS across 30 centres in the UK.23 All patients on
UKPSSR fulﬁl American European Consensus Group cri-
teria for classiﬁcation of pSS. This study selected 159
female patients with pSS who displayed a range of differ-
ent fatigue scores. Twenty-eight non-fatigued healthy
controls from the UKPSSR were also selected. The
North West Research Ethics Committee granted research
ethics approval for this study. Clinical and laboratory
data were collected prospectively using a standardised
proforma at the time of recruitment onto the UKPSSR.
Clinical variables and outcomes
Fatigue severity was measured using the Proﬁle of
Fatigue Questionnaire, which is validated for use in
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pSS.24 Physical fatigue was scored on a scale of 0–7 to
classify patients into minimal (0–1), mild (2–3), moder-
ate (4–5) and severe (6–7) fatigue groups based on
quartile scores. People from the healthy control group
were screened for the presence of fatigue using a self-
completed questionnaire. None of the controls reported
the presence of fatigue, sicca symptoms or other auto-
immune conditions. Anxiety and depression were mea-
sured using the Hospital Anxiety and Depression Score.25
Other clinical parameters included systemic disease
activity using the EULAR Sjögren’s Syndrome Disease
Activity Index (ESSDAI) and EULAR Sjögren’s Syndrome
Patient Reported Index (ESSPRI), as well as glandular
manifestations using Schirmer’s test, unstimulated oral sal-
ivary ﬂow test and EULAR Sicca Score—a measure of
overall dryness experienced by the patient.26 27
The UKPSSR holds biobanked serum samples for
each patient with pSS, which were analysed with cyto-
metric bead array-based immunoassay allowing multiple
analyses of a single sample. The following 24 cytokines
were tested: cluster of differentiation 40 ligand (CD40L),
cluster of differentiation 54 (CD54), cluster of differenti-
ation 106 (CD106), E-selectin, interferon-α (IFN-α),
interferon-γ (IFN-γ), interferon-γ-induced protein-10
(IP-10), interleukin-1β (IL-1β), interleukin-4 (IL-4),
interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10
(IL-10), interleukin-12p70 (IL-12p70), interleukin-12–
interleukin-23p40 (IL-12/IL23-p40), interleukin-17
(IL-17), interleukin-21 (IL-21), lymphotoxin-α (LT-α),
macrophage inﬂammatory protein 1α (MIP1α), macro-
phage inﬂammatory protein 1β (MIP-1β), monocyte
chemoattractant protein-1 (MCP-1), monokine induced
by γ interferon (MIG), P-selectin, regulated on activation
normal T expressed and secreted (RANTES) and tumour
necrosis factor-α (TNF-α). These analytes represent a
broad spectrum of proinﬂammatory and anti-
inﬂammatory soluble molecules with possible links to
fatigue. In addition, white cell count (WCC), lympho-
cytes, neutrophils, haemoglobin, erythrocyte sedimenta-
tion rate (ESR) and C-reactive protein (CRP) were
measured in each sample by the NHS laboratory of the
recruiting centre within a day of sample collection.
Statistical analysis
Patient demographic data are presented using median
and IQR. Clinical data are presented using mean and
SD. Signiﬁcance was determined using Wilcoxon test.
Cytokine data are presented as box plots using the
median and IQR to report key ﬁndings. Since cytokine
levels were not normally distributed, a normalising log
transformation was performed prior to analysis, after
which analysis of variance testing was used to examine
the relationship between the levels of each cytokine
analyte and the corresponding fatigue score. Spearman’s
rank correlation coefﬁcient was also used to measure
correlation between ungrouped (continuous) fatigue
scores and cytokine levels.
Ordinal logistic regression analysis was used to model
predicted fatigue level against observed fatigue level,
using all cytokines. WCC, lymphocytes, neutrophils,
ESR, CRP, ESSDAI scores and dryness scores, were also
incorporated into this model, as well as depression,
anxiety and pain scores.
All statistical tests and graphics were performed using
R version 3.1.1 and SAS JMP (Version 14) Statistical
Data Visualization software.28 29
RESULTS
Study population
Serum samples from 159 female patients with pSS with a
range of fatigue levels and 28 healthy non-fatigued
female controls from the UKPSSR were used in this
study. Patients with pSS were stratiﬁed into four groups
according to their fatigue levels. Patients were predomin-
antly Caucasian in both groups; however, the mean age
of healthy controls was younger than the pSS group.
Demographic data of cohort are summarised in table 1.
Clinical differences between pSS fatigue groups
Disease and symptom duration were not signiﬁcantly dif-
ferent between fatigue groups (table 2). Anti-Ro/La
positivity and the percentage of each group prescribed
potentially immune-altering medications (eg, hydroxy-
chloroquine or prednisolone) did not differ signiﬁcantly
across groups (table 2). Forty-three per cent of patients
overall were prescribed an immune-altering medication
and this was hydroxychloroquine in the majority of such
patients (table 2). Serum IgG levels decreased with
increasing fatigue (p=0.008) with the mean serum IgG
levels in the groups of patients with pSS with minimal
and mild fatigue being above the normal ranges
(table 2). Lymphocyte counts increased (p=0.002) with
increasing fatigue, but the values were within normal
ranges for all pSS groups (table 2). The remaining
Table 1 Demographic summary for control and pSS fatigue groups
Control Minimal (0–1) Mild (2–3) Moderate (4–5) Severe (6–7) p Value
N 28 24 44 65 26
Mean age±SD 50±13 62±10 58±14 60±12 59±13 0.005
Caucasian (%) 100 100 95.5 95.4 96.2 ns
All participants are female. Mean age was lower in the control group while ethnicity did not vary significantly across groups.
pSS, primary Sjögren’s syndrome.
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haematological parameters did not show signiﬁcant dif-
ferences between fatigue groups. Anxiety, depression,
pain, dryness and ESSPRI (overall symptom burden)
scores all increased with increasing fatigue levels
(p≤0.0001) (table 2). EULAR Sicca Score, a measure of
ocular and oral dryness, also increased with increasing
fatigue (p=0.004). However, there was no signiﬁcant
relationship between systemic disease activity (measured
using ESSDAI scores) and fatigue groups (table 2).
Cytokine differences between patients with pSS and
healthy controls
As expected, many proinﬂammatory molecules were ele-
vated among patients with pSS compared to healthy con-
trols, consistent with the inﬂammatory nature of the
condition. Speciﬁcally, CD106, IP-10, IL-17, IL-21,
MIP1α, TNF-α, LT-α, MIP1β, IFN-γ, MIG, IL-6, IL-10,
IL-12p70 and IL-12/IL23-p40 levels were signiﬁcantly
higher in patients with pSS compared with controls, with
eight of these cytokines having p values of ≤0.0001
between these participant groups (table 3). None of the
other serum proteins were signiﬁcantly different
between patients with pSS and controls.
In addition to this, there were statistical differences in
IP-10, IL-6, IL-10, IL-12, IL-17, IL-21, IFN-γ, LT-α, MIG,
MIP1α, MIP1β and TNF-α levels between healthy con-
trols and the minimally fatigued pSS groups. In all cases,
they were higher in the pSS population.
Cytokines and fatigue scores in patients with pSS
Unexpectedly, fatigue levels increased with decreasing
levels of several proinﬂammatory cytokines: IP-10
(p=0.019), TNF-α (p=0.046), LT-α (p=0.034) and IFN-γ
(p=0.022) (ﬁgure 1A–D) within the cases with pSS.
Furthermore, weak negative correlations were shown
between cytokine levels and ungrouped (continuous)
fatigue scores: IP-10—0.2190, TNF-α—0.1273, IFN-γ—
0.1985 and LT-α—0.0808. The remaining cytokines did
not display statistically signiﬁcant relationships with
fatigue levels within the cases with pSS.
Predictors of fatigue severity in pSS
Ordinal logistic regression (ﬁgure 2A, B) predicts mem-
bership of the minimal, mild, moderate and severe
fatigue groups using all 24 cytokines, WCC, lymphocytes,
neutrophils, ESR, CRP, ESSDAI scores and dryness
scores, as well as patient-reported depression, anxiety
and pain. The full model, with all parameters, correctly
predicts fatigue in 67% of cases (ﬁgure 2A). This model
with all parameters was robust to the presence or
absence of loose markers of disease activity (such as
WCC, lymphocytes, neutrophils, ESR, CRP, ESSDAI and
dryness scores), but sensitive to the presence or absence
of cytokines, depression, anxiety and pain. The model
predictions are reasonably accurate providing cytokines,
depression and pain are retained. This suggests that
measures of disease activity in pSS appear to be less
Table 2 Clinical summary for pSS fatigue groups showing mean±SD for key demographics, haematological and clinical
variables
Variable Minimal Mild Moderate Severe p Value
Age (years) 62±10 58±14 60±12 59±13 ns
Disease duration (years) 5.5±5.8 6.1±5.2 7.5±6.2 9.1±7.3 ns
Symptom duration (years) 13±10 13±11 14±11 16±13 ns
BMI (kg/m2) 25±4.4 26±4.2 26±6.3 28±7.2 ns
% Anti-Ro/La positive 91.67 95.45 83.08 92.31 ns
% Not taking any immune-altering medications 67 59 52 50 ns
% On hydroxychloroquine 17 34 37 34 ns
% On prednisolone 8 5 6 12 ns
% On ‘other’ immune-altering medications 8 2 5 4 ns
ESSDAI 5.4±5.7 7.6±8.2 5.9±5.2 7.2±6.1 ns
ESSPRI 2.9±1.3 4.3±1.4 6.6±1.4 8.3±1.1 ≤0.0001
ESSPRI pain 1.4±1.5 3.2±2.5 5.4±2.6 8±1.6 ≤0.0001
ESSPRI dryness 5.6±2.7 5.5±2.2 6.9±2.6 8.1±2 ≤0.0001
EULAR SS 5.3±2.5 5.6±2.5 6.8±2.5 7.8±2 0.0004
HADS anxiety (0–21) 3.7±2.4 6.5±3.5 8.6±4.4 12±4.9 ≤0.0001
HADS depression (0–21) 2±1.9 4±2.8 7.4±3.5 11±2.9 ≤0.0001
Hb (g/dL) 12±1.6 13±1.2 13±1.2 13±1.1 ns
WCC (×109/L) 5.5±1.4 5.2±1.5 5.2±2.0 6.3±2.7 ns
Neutrophil (×109/L) 3.5±1.1 3.3±1.3 3.2±1.5 3.7±2 ns
Lymphocyte (×109/L) 1.4±0.6 1.3±0.5 1.4±0.6 1.9±0.9 0.002
ESR (mm/h) 39±26 33±25 27±24 24±20 ns
CRP (mg/L) 6.4±5 5±4.1 5.2±5.9 6.7±5.8 ns
IgG (mg/dL) 20±8.8 18±8 15±6.5 15±4.2 0.008
BMI, body mass index; CRP, C-reactive protein; ESSDAI, EULAR Sjögren’s Syndrome Disease Activity Index; ESR, erythrocyte
sedimentation rate; ESSPRI, EULAR Sjögren’s Syndrome Patient Reported Index; EULAR SS, EULAR Sicca Score; HADS, Hospital Anxiety
and Depression Score; Hb, haemoglobin; pSS, primary Sjögren’s syndrome; WCC, white cell count.
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important than cytokines, depression and pain in accur-
ately predicting fatigue levels.
Reﬁnement of the ordinal logistic regression
model, identiﬁed IFN-γ, IP-10, depression and pain are
sufﬁcient to predict fatigue with similar (67%) accuracy
as the full model (ﬁgure 2B). This suggests that depres-
sion, pain and cytokines are the most important predic-
tors of fatigue.
Table 3 Cytokine levels in patients with pSS and healthy controls
Cytokine Controls (n=28) Cases with pSS (n=159) p Value
CD54 41882.42
31954.3, 68077.5
47915.84
36203.1, 76537.1
0.2599
RANTES 19117.12
13203.8, 28251.3
21472.56
15722.97, 28255.1
0.1643
CD106 67543.20
51824.4, 75985.4
80921.58
57934.1, 96570.5
0.0042
IL-8 37378.14
11075.6, 311730.2
35623.48
10596.6, 374424.3
0.6929
IP-10 110.24
75.0, 167.4
342.38
226.2, 540.5
<0.0001
IF 1.34
0.8, 2.2
1.48
0.7, 4.5
0.1659
IL-17 1.32
0.4, 2.0
3.28
1.3, 47.0
<0.0001
IL-21 45.33
30.6, 63.4
71.71
40.0, 782.8
0.0006
MIP1α 5.85
1.7, 101.4
99.52
6.9, 219.3
<0.0001
TNF-α 0.08
0.0, 0.1
7.00
0.1, 27.1
<0.0001
LT-α 0.33
0.2, 0.6
2.5
0.5, 13.0
<0.0001
P-selectin 7385.86
5802.8, 8894.1
8212.16
5148.01, 11983.12
0.3287
MCP-1 131.62
95.3, 221.7
170.42
121.8, 318.2
0.1061
E-selectin 2515.06
1691.2, 3588.5
2862.34
1992.0, 4241.0
0.3213
MIP1β 78.96
27.0, 136.5
178.40
97.3, 333.8
<0.0001
IFN-γ 1.90
0.5, 3.2
2.97
1.4, 10.6
0.0018
MIG 125.90
84.5, 244.0
986.32
458.4, 2593.4
<0.0001
CD40 ligand 2838.26
1893.4, 3559.4
2449.40
1825.4, 3239.5
0.1065
IL-6 938.18
506.7, 1537.1
1544.46
836.5, 2931.9
0.0020
IL-1β 126
45.8, 698.7
271.23
47.7, 738.2
0.3767
IL-10 50.68
9.9, 360.0
490.90
129.6, 881.9
<0.0001
IL-12p70 16.63
8.40, 25.0
27.18
13.41, 206.4
0.0024
IL-4 0.00
0.00, 0.00
0.00
0.00. 0.00
0.3322
IL-12.IL-3p40 0.00
0.00, 0.00
0.00
0.00, 0.00
0.0117
Bold typeface indicates significance.
Generally cytokines were significantly higher in patients with pSS compared to controls. Values in table represent median and 25th, 75th
centile (pmol/L).
CD, cluster of differentiation; IFN-γ, interferon-γ; IL, interleukin; IP-10, interferon-γ-induced protein-10; LT-α, lymphotoxin-α; MCP-1, monocyte
chemoattractant protein-1; MIG, monokine induced by γ interferon; MIP, macrophage inflammatory protein; pSS, primary Sjögren’s syndrome;
RANTES, regulated on activation normal T expressed and secreted; TNF-α, tumour necrosis factor-α.
Howard Tripp N, et al. RMD Open 2016;2:e000282. doi:10.1136/rmdopen-2016-000282 5
Connective tissue diseases
Figure 1 Box plot showing median cytokine levels and IQRs for (A) IP-10, (B) TNF-α, (C) LT-α and (D) IFN-γ in controls and
pSS fatigue groups. In all four cases, the levels of anti-inflammatory cytokines are significantly higher in patients with pSS. In
addition, all four show an inverse relationship between fatigue severity and cytokine levels. Fatigue levels fall with increasing
levels of the four cytokines. IFN-γ, interferon-γ; IP-10, interferon-γ-induced protein-10; LT-α, lymphotoxin-α; pSS, primary
Sjögren’s syndrome; TNF-α, tumour necrosis factor-α.
Figure 2 (A) Full ordinal logistic regression model with all parameters. This model analyzes observed fatigue values in order to
predict fatigue values based on the following variables: all 24 cytokines, WCC, lymphocytes, neutrophils, ESR, CRP, ESSDAI
scores, dryness scores, depression, pain and anxiety scores. It then compares the predicted with the observed values to
ascertain the accuracy of the model. All of these variables predict fatigue level correctly in 67% of cases. (B) shows that IFN-γ,
IP-10, depression and pain alone predicted fatigue level with 67% accuracy, which was as effective as the full-model.
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DISCUSSION
Our study demonstrates that patients with pSS with
higher levels of fatigue had lower levels of the proin-
ﬂammatory cytokines IP-10, TNF-α, LT-α and IFN-γ than
patients with pSS with low levels of fatigue. It should be
noted, however, that the serum levels of many cytokines
among even the fatigued participants with pSS were still
higher than non-fatigued healthy individuals. Our obser-
vation that the magnitude of inﬂammatory response
correlated inversely with fatigue levels does not, however,
support a simple concept of higher levels of inﬂamma-
tion leading to worse fatigue.
One possible explanation is that regulatory mechan-
isms of inﬂammation may be responsible for sustained
fatigue after an initial inﬂammatory response. This
hypothesis is illustrated in ﬁgure 3, which depicts an anti-
inﬂammatory negative feedback loop, reducing inﬂamma-
tory markers, but resulting in persistent fatigue. Thus,
although fatigue is induced by proinﬂammatory cytokines
as part of an ‘adaptive behaviour response’, which has
evolved as a protective motivational state during and fol-
lowing an infection, a potentially maladaptive immune
response may contribute to the maintenance of persistent
fatigue after clearance of a pathogen or in a chronic
inﬂammatory state.30 We suggest that immune-modulatory
and anti-inﬂammatory mechanisms may be inappropri-
ately expressed in patients suffering from fatigue. Further
research into such anti-inﬂammatory pathways and regu-
latory mechanisms of inﬂammation might be insightful in
the understanding of the biological basis of persistent
fatigue in chronic diseases.
This hypothesis may be further supported by a recent
study by Hornig et al,31 which demonstrated lower levels
of the proinﬂammatory cytokines IL-17, IL-8, IP-10, and
TNF-α and soluble Fas ligand in patients with CFS com-
pared with control groups. This study also found inverse
correlations with cytokine levels and illness duration in
patients with CFS. Speciﬁcally, the proinﬂammatory cyto-
kines IFN-γ and IL-12p40 were more markedly elevated
in the short-duration compared to the long-duration
CFS group. This suggests that the immunological
changes seen in CFS are dynamic and may change with
time as illness duration increases. These observations are
consistent with the concept of fatigue being mediated by
negative feedback/homeostatic mechanisms following
an initial or sustained period of inﬂammation. An
increased anti-inﬂammatory response has also been
observed in a number of other CFS studies. In 2007, ter
Wolbeek et al found higher levels of anti-inﬂammatory
cytokines (IL-10 and IFN-γ/IL-10 ratios) and lower levels
of proinﬂammatory cytokines (IL-6 and TNF-α) in ado-
lescents with CFS compared to healthy controls.32
Reduced phytohemagglutinin-stimulated IFN-γ produc-
tion by CD4+ T cells has been shown in CFS.33 This may
support the idea that anti-inﬂammatory or regulatory
pathways play some role in mediating persistent fatigue,
after initial inﬂammatory insults.
It is also noteworthy that IP-10, TNF-α and IFN-γ have
been implicated in the study by Hornig and colleagues
as well as our current study. IFN-γ, produced by natural
killer as well as T cells, helps to initiate a cellular
response to infection. TNF-α is secreted as part of an
acute phase reaction to mediate protective immune
responses to infection. IP-10 is secreted from cells after
stimulation by IFN-γ and is a chemoattractant for acti-
vated T cells to sites of inﬂammation.34 These cytokines
are linked to an activated Th1 response, raising the intri-
guing possibility that dysregulation of Th1 responses
may be linked to development of fatigue. A bias towards
Th2 responses in CFS has, in fact, been demonstrated in
a number of CFS studies and may be an important com-
ponent in mediating fatigue.35
However, few cytokine abnormalities in CFS and other
fatigue-associated chronic conditions have been consist-
ently demonstrated across different studies. One possible
explanation is the confounding psychosocial factors
present in the patient groups in different studies.
Indeed, depression and pain were important predictors
of fatigue in our study, supporting the concept of a bio-
psychological model of fatigue. The importance of psy-
chological factors in pSS-associated fatigue is supported
by two recent studies. Karageorgas et al36 found that
anxiety, depression and ﬁbromyalgia play a major role in
pSS-associated fatigue, whereas van Leeuwen et al37
demonstrated that distinct psychological proﬁles are dif-
ferentially associated with fatigue in pSS. However,
removing depression, pain and anxiety did not fully
disrupt the regression model in this study. In contrast,
removing cytokines disrupted the performance of the
model suggesting that while pain and depression appear
to play some role in fatigue, inﬂammatory/anti-
inﬂammatory cascades may play a larger role. Further
work is however necessary to understand this likely
complex interplay and overlap between multiple psycho-
social and biological factors, which may inﬂuence levels
of fatigue.
Some of the strengths of this study include (1) a large,
clinically well-deﬁned patient group with clear diagnostic
criteria; (2) minimal demographic variation between
fatigue groups within the pSS cohort; (3) a validated
fatigue measure for use in pSS and (4) extensive charac-
terisation of the cytokine proﬁles.
We aimed to minimise potential gender differences in
cytokine proﬁles by using a female study population;
however, this may mean that such data may not be
applicable to men with pSS or indeed fatigue. Although
there were signiﬁcant differences in age between healthy
volunteers and cases with pSS, age differences between
pSS fatigue groups were not statistically signiﬁcant and it
was within this pSS cohort that the analysis of fatigue
and cytokine levels, and ordinal regression took place. It
is also worth mentioning that pSS fatigue groups were
not signiﬁcantly different in terms of anti-Ro/La positiv-
ity or immune-altering medications used. This is relevant
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as hydroxychloroquine and prednisolone can affect a
cytokine proﬁle and therefore suggests that cytokine dif-
ferences are not due to differential medication prescrib-
ing across groups.38
There are however limitations in this study. First,
unlike a longitudinal study, the cross-sectional nature of
the study does not permit within-patient comparisons.
Second, cytokine levels may vary considerably within a
short space of time and their presence in the blood may
be inﬂuenced by multiple factors, including fatigue
itself. While cytokines may indeed affect fatigue, fatigue
may also affect cytokine levels as part of a two-way loop.
Furthermore, there could be other possible contributing
factors of fatigue among patients with pSS, which have
not been taken into consideration.
To conclude, immune dysfunction or dysregulation
may contribute to the development of fatigue in pSS
and other chronic immunological diseases, although
further characterisation of the mechanisms involved is
needed. In particular, evaluation of potential negative
feedback pathways inappropriately activated in patients
experiencing fatigue, as well as studies examining
Figure 3 Hypothetical model of
fatigue in a chronic immunological
condition. This model suggests
that anti-inflammatory
mechanisms may have a part to
play in the persistent fatigue in
chronic inflammatory diseases.
When presented with an immune
infective challenge, the immune
response triggers inflammatory
pathways, which triggers a
cytokine-mediated behavioural
response, which has been called
‘sickness behaviour’. Additionally,
the immune (inflammatory)
response also activates
homeostatic regulatory pathways.
In the healthy patient (A), the
cytokine balance is restored and
the behavioural pathways
inactivated, leading to recovery.
However, if this system is
dysregulated (B) and exposed to
constant immune challenge, as in
the case of pSS, chronic
inflammation results, which
triggers an inappropriate
anti-inflammatory response. We
postulate that this exaggerated
immune regulatory response
turns what was an adaptive
behavioural response into
persistent and pathological
chronic fatigue. This may help to
explain why studies have found
raised levels of anti-inflammatory
cytokines in patients with more
severe fatigue and why
proinflammatory cytokines
decrease as fatigue increases in
this study. The fatigued patient is
caught in a pathological feedback
loop with dysregulation of the
immune system, cytokine. pSS,
primary Sjögren’s syndrome.
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different phenotypes and their corresponding levels of
fatigue within a deﬁned patient population, would be
valuable areas for future research.
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